E7386, a non-specific CBP-β-catenin interaction antagonist developed by Eisai, also showed anti-tumor activity in pre-clinical tumor models with activated Wnt/β-catenin signaling [236,237]. This evidence concerns the gene CREBBP and neoplasm.